Recently diagnosed with HIV? Click here

ROaR+

Clinical trial • Enrolling • 24 March 2011
This trial is enrolling now. Depending on eligibility and available places in your area, you may be able to enrol in this trial.

About this trial

This is a research study into the effects of three drugs used to treat HIV infection.

Some drugs used to treat HIV have been associated with changes in blood fatsA type of fat in the blood. Elevated triglyceride levels may be a side effect of some anti-HIV drugs. (such as cholesterolAn essential component of cell membranes and nerve fibre insulation, cholesterol is important for the metabolism and transport of fatty acids and the production of hormones and Vitamin D. Cholesterol is manufactured by the liver, and is also present in certain foods. High blood cholesterol levels have been linked to heart disease and may be a side effect of some anti-HIV medications.) that could be harmful over the long-term because these blood fat changes have been associated with a small, increased risk of heart disease and stroke in some studies of adults with HIV. Now that HIV can be controlled for long periods in most patients, and because heart disease is one of the biggest causes of illness and death in the general population, it is important to develop new HIV treatments that control HIV effectively but do not cause abnormal blood fatsA fat..

HypothesisA supposition or assumption advanced as a basis for reasoning or argument, or as a guide to experimental investigation.: that raltegravir will result in less post-prandial lipid disturbances than ritonavir-boosted darunavir.

Official title:Post-prandial Lipid Effects of Raltegravir (RAL) vs Ritonavir-boosted Darunavir (DRV-r) in Anti-retroviral Therapy (ART)-Naive Adults
What is this trial studying?Side effect management – ritonavir, Truvada, darunavir, raltegravir
Start date:November 2010

This may be the proposed or expected start date for trials which have not yet started.

How many participants will this trial enrol?30

The exact number of participants may be lower or slightly higher than this. Some trials also have specific quotas for participants from each state, city or clinic.

How long is this trial planned to go for?Participants in this trial will be asked to follow the trial protocol for 24 weeks.
Links to further information:
Tags:heart disease

Who can enrol in this trial?

You may be eligible to participate in this trial if you meet the following criteria:

  • At least 18 years old
  • Have never taken HIV treatments
  • CD4 count below 500 cells/mm3
  • Viral load at least 10000 copies/ml

This is a summary of key inclusion and exclusion criteria for this trial. There may be other criteria which may exclude some people from participation in this trial. Some laboratory tests may also be required. Consult your doctor, or view the trial protocol or informed consent documentation to see the full range of exclusion and inclusion criteria.

If you are interested in enrolling in this trial

Before making the decision to participate in any clinical trial, NAPWA recommends that you discuss the potential benefits and risks of participation with your treating doctor. Your doctor can also provide advice about your eligibility to participate in the trial.

While NAPWA has taken every care to compile the information on this page and to keep it up-to-date, we cannot guarantee its correctness and completeness.

  • You can print this page to take it with you to the doctor – just use your browser's 'print' function.
  • Before making the decision to participate in any clinical research, read our background information.
  • Email NAPWA if you have any questions or comments about this trial
Text size: font smallerfont normalfont larger print-friendly version of this pagePDF version of this pageemail this page to a friend

This Clinical trial was first published on 24 March 2011 — more than one year ago.

While the content of this clinical trial was checked for accuracy at the time of publication, NAPWA recommends checking to determine whether the information is the most up-to-date available, especially when making decisions which may affect your health.

This article may contain medical information. NAPWA makes every reasonable effort to ensure the information on this website is accurate, reliable and up-to-date, including obtaining technical reviews by medically-qualified reviewers, however the authors of information on this website are not qualified to give medical advice, except where explicitly stated.

The content of this website is intended to support, not replace, the relationship between people living with HIV/AIDS and their medical advisers, and is not intended as a substitute for medical advice.

Website links

HIV Clinical Trials update

Recently updated entries from the NAPWA Clinical Trials database.

more